Revolution Medicines Sees Unusually High Options Volume (NASDAQ:RVMD)

Key Points

• Unusual put activity: Traders bought 12,797 put options on RVMD on Friday, a ~131% increase versus the average, signaling elevated bearish betting against the stock.
• Analyst backdrop mixed with a "Buy" tilt: Four analysts rate RVMD as Strong Buy and 16 as Buy (consensus "Buy"), but the average target price of $78.94 is below Friday's close of $97.15.
• Negative company signals — insider selling and earnings miss: Insiders sold 149,592 shares (~$15.0M) over the past three months (notably March 17 sales), and the company missed quarterly EPS estimates at ($1.86) vs. ($1.56) expected.

Revolution Medicines, Inc. (NASDAQ:RVMD - Get Free Report) was the target of some unusual options trading on Friday. Stock traders acquired 12,797 put options on the stock. This represents an increase of approximately 131% compared to the average volume of 5,546 put options.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on RVMD. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Revolution Medicines in a research note on Thursday, January 22nd. UBS Group assumed coverage on Revolution Medicines in a research report on Friday, February 27th. They issued a "buy" rating for the company. Wedbush reissued an "outperform" rating on shares of Revolution Medicines in a research report on Friday, January 9th. Benchmark reissued an "overweight" rating on shares of Revolution Medicines in a research note on Tuesday, February 17th. Finally, Evercore raised shares of Revolution Medicines to a "strong-buy" rating in a research note on Wednesday, February 25th. Four investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, Revolution Medicines presently has an average rating of "Buy" and an average target price of $78.94.

Revolution Medicines Stock Down 2.2%

NASDAQ RVMD traded down $2.14 on Friday, hitting $97.15. 384,525 shares of the stock were exchanged, compared to its average volume of 3,437,770. Revolution Medicines has a fifty-two week low of $29.17 and a fifty-two week high of $124.49. The company has a 50-day moving average price of $103.42 and a 200-day moving average price of $76.40. The company has a quick ratio of 7.14, a current ratio of 7.14 and a debt-to-equity ratio of 0.16. The company has a market cap of $19.25 billion, a PE ratio of -16.45 and a beta of 0.99.

Revolution Medicines (NASDAQ:RVMD - Get Free Report) last issued its earnings results on Wednesday, February 25th. The company reported ($1.86) EPS for the quarter, missing analysts' consensus estimates of ($1.56) by ($0.30). During the same period in the previous year, the business posted ($1.12) EPS. Sell-side analysts anticipate that Revolution Medicines will post -3.49 EPS for the current fiscal year.

Insider Transactions at Revolution Medicines

In other news, insider Stephen Michael Kelsey sold 4,302 shares of the firm's stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $99.48, for a total value of $427,962.96. Following the transaction, the insider directly owned 295,398 shares of the company's stock, valued at approximately $29,386,193.04. This trade represents a 1.44% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CFO Jack Anders sold 2,753 shares of the company's stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $99.48, for a total transaction of $273,868.44. Following the sale, the chief financial officer directly owned 125,512 shares of the company's stock, valued at approximately $12,485,933.76. This represents a 2.15% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 149,592 shares of company stock valued at $15,010,732. Insiders own 8.20% of the company's stock.

Institutional Trading of Revolution Medicines

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Indiana Trust & Investment Management Co acquired a new position in shares of Revolution Medicines in the 4th quarter valued at $32,000. Global Retirement Partners LLC lifted its position in Revolution Medicines by 1,002.8% in the fourth quarter. Global Retirement Partners LLC now owns 397 shares of the company's stock valued at $32,000 after acquiring an additional 361 shares during the last quarter. Torren Management LLC acquired a new position in Revolution Medicines in the fourth quarter valued at $33,000. Arax Advisory Partners purchased a new position in shares of Revolution Medicines during the fourth quarter worth about $38,000. Finally, GAMMA Investing LLC increased its position in shares of Revolution Medicines by 45.1% during the third quarter. GAMMA Investing LLC now owns 837 shares of the company's stock worth $39,000 after purchasing an additional 260 shares in the last quarter. Institutional investors and hedge funds own 94.34% of the company's stock.

Key Headlines Impacting Revolution Medicines

Here are the key news stories impacting Revolution Medicines this week:

• Positive Sentiment: Large institutional buying and heavy ownership from firms (General Atlantic, Norges Bank, Avoro, UBS, Polar Capital) signals strong long-term conviction from major investors, which can provide floor support for the share price. Institutional Summary
• Positive Sentiment: Analyst coverage is broadly positive — recent upgrades/initiations (Evercore, UBS, Wedbush, Benchmark) and a consensus “Buy” tilt may attract buyer interest and help stabilize the stock over time. Analyst Coverage
• Neutral Sentiment: Company profile — clinical-stage biotech focused on RAS-pathway oncology (RMC-4630, RMC-6291, RMC-6236). High upside if trials read out well, but clinical/readout risk is intrinsic. Company Profile
• Neutral Sentiment: Recent earnings (Feb. 25) missed estimates (EPS -$1.86 vs. -$1.56 consensus), underscoring continued cash burn and negative EPS expectations for the year — a typical headwind for a development-stage biotech. Earnings Summary
• Negative Sentiment: Multiple senior insiders sold shares on March 17 (largest: Mark Goldsmith 12,871 sh; COO Margaret Horn 4,583 sh; CFO Jack Anders 2,753 sh; plus smaller sales by others) at ~ $99.48 — sizable insider selling can weigh on sentiment and intra-day liquidity. SEC filings: Goldsmith SEC Filing · Horn SEC Filing
• Negative Sentiment: Insider sales by multiple executives (Xiaolin Wang, Lin Wei and others) collectively reduce insider ownership stakes and may be read as liquidity-taking by insiders, pressuring near-term sentiment. SEC filings: Wang SEC Filing · Wei SEC Filing

Revolution Medicines Company Profile

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company's research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.